• Fremanezumab-vfrm comes as a prefilled syringe which should be given as a subcutaneous injection (under the skin).
• The injection sites include areas of the abdomen, upper arm or the thigh and the sites can be switched each time when an injection is given.
• Never inject into thickened, scaly, tender, damaged, red or bruised skin.
• Fremanezumab-vfrm injections should be given only by a healthcare professional who is properly trained in administrating the prefilled syringe.
• While giving 675 mg dose of fremanezumab-vfrm injection, use three separate injections of 225 mg that can be given in the same site but not in the same spot.
• Before injecting, it is necessary to keep the fremanezumab-vfrm vial outside the refrigerator and allow it to come to room temperature for at least 30 minutes.
• Placing the prefilled syringe in a bowl of hot water or in a microwave oven with the intention of warming the refrigerated prefilled syringe is not advised.
• It is generally advised to inspect the contents of the vial for the presence of any solid or visible particles and discoloration or any change in appearance. Discard the vial contents if such things are present.
• 225 mg monthly or
• 675 mg quarterly (once every three months) given as three injections of 225 mg
When switching between the dosing options from once a month to once every three months or vice versa, it is always safe to give the first dose of the new regimen as per the old schedule and then follow the new schedule.
• If there is an allergy to fremanezumab-vfrm
• Children
Caution is required when using fremanezumab-vfrm in pregnant and breastfeeding women to avoid the risk caused to the fetus or the baby.
• If a missed dose is 225 mg, then take the next dose after one month from the last dose.
• If a missed dose is 675 mg, then take the next dose after three months from the date of the last dose.
• Never take a double dose of fremanezumab-vfrm to make up for the missed dose which can be harmful.
• The injection sites include areas of the abdomen, upper arm or the thigh and the sites can be switched each time when an injection is given.
• Never inject into thickened, scaly, tender, damaged, red or bruised skin.
• Fremanezumab-vfrm injections should be given only by a healthcare professional who is properly trained in administrating the prefilled syringe.
• While giving 675 mg dose of fremanezumab-vfrm injection, use three separate injections of 225 mg that can be given in the same site but not in the same spot.
• Before injecting, it is necessary to keep the fremanezumab-vfrm vial outside the refrigerator and allow it to come to room temperature for at least 30 minutes.
• Placing the prefilled syringe in a bowl of hot water or in a microwave oven with the intention of warming the refrigerated prefilled syringe is not advised.
• It is generally advised to inspect the contents of the vial for the presence of any solid or visible particles and discoloration or any change in appearance. Discard the vial contents if such things are present.
Dosage & When it is to be taken
The recommended dose of fremanezumab-vfrm can be selected based on the following two dosing options-• 225 mg monthly or
• 675 mg quarterly (once every three months) given as three injections of 225 mg
When switching between the dosing options from once a month to once every three months or vice versa, it is always safe to give the first dose of the new regimen as per the old schedule and then follow the new schedule.
When it is not to be taken (Contraindications)
Fremanezumab-vfrm should not be used in patients-• If there is an allergy to fremanezumab-vfrm
• Children
Caution is required when using fremanezumab-vfrm in pregnant and breastfeeding women to avoid the risk caused to the fetus or the baby.
What if you Miss a Dose of Fremanezumab-vfrm?
• If a dose of fremanezumab-vfrm is missed, take the missed dose as soon as possible.• If a missed dose is 225 mg, then take the next dose after one month from the last dose.
• If a missed dose is 675 mg, then take the next dose after three months from the date of the last dose.
• Never take a double dose of fremanezumab-vfrm to make up for the missed dose which can be harmful.
